Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has been assigned an average recommendation of “Hold” from the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $25.00.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of Aquinox Pharmaceuticals in a research report on Tuesday, November 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th.
Institutional investors and hedge funds have recently made changes to their positions in the company. Investment Centers of America Inc. bought a new position in Aquinox Pharmaceuticals in the third quarter valued at approximately $175,000. Citadel Advisors LLC purchased a new stake in shares of Aquinox Pharmaceuticals in the third quarter worth $194,000. Bank of New York Mellon Corp grew its stake in shares of Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after acquiring an additional 3,299 shares during the last quarter. Sphera Funds Management LTD. grew its stake in shares of Aquinox Pharmaceuticals by 21.7% in the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after acquiring an additional 13,450 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after acquiring an additional 2,691 shares during the last quarter. Institutional investors own 96.25% of the company’s stock.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.12. research analysts predict that Aquinox Pharmaceuticals will post -2.08 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals Inc (AQXP) Receives Average Recommendation of “Hold” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/19/aquinox-pharmaceuticals-inc-aqxp-receives-average-recommendation-of-hold-from-brokerages-2.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.